Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYME THERAPEUTICS INC Form 4 February 04, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Shaffer James P Issuer Symbol HALOZYME THERAPEUTICS (Check all applicable) INC [HALO] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X_Officer (give title Other (specify (Month/Day/Year) below) below) 11388 SORRENTO VALLEY 02/02/2014 VP & Chief Commercial Officer ROAD (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Applicable Line) Filed(Month/Day/Year) _X_ Form filed by One Reporting Person Form filed by More than One Reporting SAN DIEGO, CA 92121 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 4. Securities Acquired 5. Amount of 2. Transaction Date 2A. Deemed 3. 6. Ownership 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of Securities Form: Direct Indirect (Instr. 3) any Code (D) Beneficially (D) or Beneficial (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Price Code V Amount (D) Common 10.387 02/02/2014 Μ A \$0 D 47,919 (1) Stock Common 1,242 02/02/2014 \$0 D M Α 49,161 (2) Stock Common 4.864 02/04/2014 Μ A \$0 54,025 D (3) Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	\$ 0	02/02/2014		М	16,204	02/02/2014	02/02/2022	Common Stock	16,204
Restricted Stock Units	\$ 0	02/02/2014		М	2,084	02/02/2014	02/02/2022	Common Stock	2,084
Restricted Stock Units	\$ 0	02/04/2014		М	7,500	02/04/2014	02/04/2023	Common Stock	7,500

Reporting Owners

vner Officer	0.1
	Other
VP & Chief Commercial Officer	
	VP & Chief Commercial Officer

Signatures

By: Jean Liu, Attorney-in-fact For: James P. 02/04/2014 Shaffer

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents net settlement for the vesting of 16,204 shares of a restricted stock unit award granted in February 2012. Upon vesting on (1) February 2, 2014, the reporting person received a settlement of 10,387 shares of Halozyme common stock. 5,817 shares were withheld as

Date

- payment for minimum statutory tax withholding requirement.
- (2) Represents net settlement for the vesting of 2,084 shares of a restricted stock unit award granted in February 2012. Upon vesting on February 2, 2014, the reporting person received a settlement of 1,242 shares of Halozyme common stock. 842 shares were withheld as

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

payment for minimum statutory tax withholding requirement.

Represents net settlement for the vesting of 7,500 shares of a restricted stock unit award granted in February 2013. Upon vesting on

(3) February 4, 2014, the reporting person received a settlement of 4,864 shares of Halozyme common stock. 2,636 shares were withheld as payment for minimum statutory tax withholding requirement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.